Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
Titel:
Pembrolizumab for locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma (KEYNOTE-629 study): an open-label, nonrandomized, multicenter, phase II trial
Auteur:
Hughes, B.G.M. Munoz-Couselo, E. Mortier, L. Bratland, Å. Gutzmer, R. Roshdy, O. González Mendoza, R. Schachter, J. Arance, A. Grange, F. Meyer, N. Joshi, A. Billan, S. Zhang, P. Gumuscu, B. Swaby, R.F. Grob, J.-J.